Neoadjuvant cobolimab and dostarlimab followed by surgery and adjuvant dostarlimab may confer benefits over perioperative pembrolizumab in patients with high-risk, resectable melanoma.

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

But health policy analysts say prior authorization — a system that forces some people to delay care or abandon treatment — may continue to pose serious health consequences for affected patients. That ...

Before attempting prior authorization reform via legislation and regulations, the HHS has requested that insurance companies voluntarily pledge to make changes.

Roughly half of patients had sustained reductions in depression and anxiety up to 2 years after receiving psilocybin and psychotherapy.

To our knowledge, CONTACT-02 is the first phase 3 study of a tyrosine kinase inhibitor-immune checkpoint inhibitor combination to show a significant improvement in progression-free survival in ...

Preoperative stereotactic radiation therapy (SRT) could expedite treatment for cancer patients with brain metastases and is as safe as postoperative SRT, according to preliminary findings published in ...

Adding subcutaneous daratumumab to KRd increased the likelihood of MRD negativity in patients with newly diagnosed MM, regardless of transplant eligibility.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised ...